T1	p 100 135	patients with early breast cancer :
T2	p 183 212	European Cooperative Oncology
T3	p 314 347	patients with early breast cancer
T4	p 1026 1040	receiving > or
T5	p 1972 1985	very low risk
T6	i 25 48	dose-dense FEC regimens
T7	i 54 75	growth factor support
T8	i 80 96	adjuvant therapy
T9	i 221 278	CECOG ) . Addition of epirubicin to adjuvant chemotherapy
T10	i 431 441	dose-dense
T11	i 474 522	fluorouracil/epirubicin/cyclophosphamide ( FEC )
T12	i 551 559	FEC ( 60
T13	i 592 623	standard chemotherapy and FEC (
T14	i 696 732	intermediate dose-dense FEC regimens
T15	i 777 796	FEC ( 75 ) or FEC (
T16	i 819 824	drugs
T17	i 886 904	pegfilgrastim 6 mg
T18	i 917 939	subcutaneous injection
T19	i 1124 1127	FEC
T20	i 1139 1144	FEC (
T21	i 1179 1182	FEC
T22	i 1185 1199	75 ) infusions
T23	i 1242 1245	FEC
T24	i 1248 1262	90 ) infusions
T25	i 1413 1421	FEC ( 90
T26	i 1524 1527	FEC
T27	i 1530 1532	90
T28	i 1757 1767	( FEC ( 90
T29	i 1856 1872	dose-dense FEC (
T30	i 1882 1887	FEC (
T31	o 646 654	toxicity
T32	o 977 985	efficacy
T33	o 1306 1311	delay
T34	o 1317 1363	adverse events and personal/logistical reasons
T35	o 1375 1384	reduction
T36	o 1439 1486	diarrhoea . Grade 3-4 haematological toxicities
T37	o 1566 1588	of febrile neutropenia
T38	o 1632 1638	events
T39	o 1654 1700	in liver enzymes and gastrointestinal events ;
T40	o 1784 1837	serious adverse events ( vomiting and throat oedema )
T41	o 1989 2009	Grade 3-4 toxicity .